Clinical trial
A Phase II Study of the Histone Deacetylase Inhibitor Panobinostat (LBH589) in Patients With Advanced Small Cell Lung Cancer (SCLC)
NCT01222936 is registered in ClinicalTrials.gov with Southern Europe New Drug Organization as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II Study of the Histone Deacetylase Inhibitor Panobinostat (LBH589) in Patients With Advanced Small Cell Lung Cancer (SCLC)
- Lead sponsor
- Southern Europe New Drug Organization
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- May 31, 2008
- Completion date
- August 31, 2010
- Enrollment
- 21 (actual)
- Sites
- 8
Conditions
As the registry lists them; a condition with its own page is linked.